Workflow
RML(301050)
icon
Search documents
雷电微力:公司具备芯片设计能力
Zheng Quan Ri Bao· 2026-01-22 10:10
Group 1 - The company has chip design capabilities and the core chips are self-developed, but it does not engage in chip manufacturing [2]
雷电微力:截至2025年12月31日股东总户数为38848户
Zheng Quan Ri Bao Wang· 2026-01-22 09:40
Core Viewpoint - LeiDian Micro Power (301050) reported that as of December 31, 2025, the total number of shareholders is expected to be 38,848 [1] Summary by Category - Company Information - LeiDian Micro Power anticipates having a total of 38,848 shareholders by the end of 2025 [1]
雷电微力(301050.SZ):具备芯片设计能力,相关核心芯片为自主研发
Ge Long Hui· 2026-01-22 06:59
Core Viewpoint - The company, 雷电微力 (301050.SZ), has indicated its capability in chip design, with its core chips being independently developed, but it does not engage in the chip manufacturing process [1]. Group 1 - The company possesses chip design capabilities [1] - The core chips are independently developed by the company [1] - The company does not involve itself in the chip manufacturing segment [1]
6G第二阶段技术试验已启动 上市公司前瞻布局抢占先机
Group 1 - The global share of China's essential patents for 5G standards has reached 42%, and the first phase of 6G technology trials has been completed, with over 300 key technology reserves formed [2] - The development of 6G technology is entering a critical window, with significant focus on the integration of low-orbit satellite networks and a comprehensive space-ground-sea network [2] - Companies are actively engaging in 6G-related business, with a focus on millimeter-wave technology as a core frequency band for 6G [3] Group 2 - Companies like 创远信科 are upgrading testing technologies and instruments towards higher frequency bands and greater bandwidth, with a focus on terahertz testing and AI communication testing [3] - 昂瑞微 is targeting the U6G frequency band and developing high-performance components, including high-power amplifiers and low-noise amplifiers, to enhance their competitive edge in RF solutions [4] - 紫光股份 is leveraging its strengths in ICT infrastructure to provide comprehensive ICT services for 6G networks, participating in various hardware and software service projects [4] Group 3 - 中兴通讯 has been actively involved in the IMT 2030 (6G) promotion group, contributing to testing and research in key technology areas such as 6G and AI integration [4] - 创远信科 has initiated the second phase of 6G technology trials and is focusing on the application of 6G+AI technology in specific scenarios like satellite internet and smart connected vehicles [5] - 瑞可达 is developing solutions for 6G communication and commercial satellite applications, while 臻镭科技 is positioning itself as a core chip supplier for 6G satellite internet [5]
雷电微力(301050.SZ):公司产品没有应用于人形机器人领域
Ge Long Hui· 2026-01-21 12:57
格隆汇1月21日丨雷电微力(301050.SZ)在互动平台表示,公司产品没有应用于人形机器人领域。 ...
雷电微力(301050.SZ):自研芯片已批量内配于自有微系统产品
Ge Long Hui· 2026-01-21 07:23
Group 1 - The core products of the company, T/R components and array antennas, have been mass-produced and applied in specialized market fields such as radar and communication, which are the main sources of the company's revenue [1] - The company's self-developed chips have been batch-integrated into its own micro-system products [1]
雷电微力:自研芯片已批量内配于自有微系统产品
Ge Long Hui· 2026-01-21 07:22
Core Viewpoint - The company, 雷电微力 (301050.SZ), has successfully scaled production of its core products, T/R components and array antennas, which are primarily used in radar and communication markets, contributing significantly to its revenue [1] Group 1 - The company's core products, T/R components and array antennas, are now in mass production [1] - These products are applied in specialized market fields such as radar and communication [1] - The specialized market is the main source of the company's operating revenue [1] Group 2 - The company has developed its own chips, which are now being integrated in bulk into its proprietary micro-system products [1]
雷电微力:公司星间链路毫米波微系统已配套于北斗导航卫星
Core Viewpoint - The company, 雷电微力, is focusing on expanding its satellite communication business by leveraging its advanced technologies and successful projects in the field [1] Group 1: Company Products and Technologies - The company's main products, T/R components and array antennas, provide reliable anti-jamming support for satellite communications through high-precision phase and amplitude control and adaptive beamforming technology [1] - The self-developed inter-satellite link millimeter-wave microsystem has been successfully integrated with the BeiDou navigation satellites, showcasing the company's engineering capabilities in aerospace-grade projects [1] Group 2: Business Expansion - The company plans to actively expand its satellite communication business, building on the expertise gained from the BeiDou project [1]
百利天恒BL-B01D1上市申请获受理 系适用于食管癌治疗ADC药物
Zhong Zheng Wang· 2026-01-20 08:00
Group 1 - The National Medical Products Administration (NMPA) accepted the market application for the first-class new drug BL-B01D1, which is indicated for recurrent or metastatic esophageal squamous cell carcinoma that has failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] - BL-B01D1 (Iza-bren) is a globally innovative dual-antibody ADC that blocks signals from EGFR and HER3 to tumor cells, inhibiting their proliferation and survival [1] - The drug's mechanism includes antibody-mediated endocytosis, which releases therapeutic payloads that induce genotoxic stress, ultimately leading to tumor cell death [1] Group 2 - In December 2023, the company entered into an exclusive licensing and collaboration agreement with Bristol-Myers Squibb (BMS) for the global development and commercialization of Iza-bren [2] - BMS will pay the company an upfront fee of $800 million, along with two milestone payments of $250 million each; additional payments could reach up to $7.1 billion based on development, registration, and sales milestones [2] - The total potential deal value could reach $8.4 billion, setting a record for the highest total price for a single drug licensing agreement in the ADC field [2] - Currently, there are only 10 biopharmaceutical new drugs approved for esophageal cancer treatment globally, with no ADCs approved yet; if approved, BL-B01D1 will be the first ADC for esophageal cancer treatment [2]
18家蓉企上榜
Xin Lang Cai Jing· 2026-01-18 17:25
Group 1 - The core viewpoint of the article is the release of the first "2025 Hurun China Unicorn Graduation List," which identifies 796 companies valued over $1 billion that have gone public since 2000, with 18 companies from Chengdu making the list, ranking seventh nationally [1] Group 2 - The 18 Chengdu companies listed include: Xinyi Sheng, Kelun Botai Biotech, AVIC Drone, Chengdu Huamei, Jiachitech, Dekang Agriculture, Huatu Shanding, Chabaidao, Leidian Weili, Tianwei Food, Qiaoyuan Co., Kangnuo Ya, Zhenxin Technology, Fusenmei, Bomei, XGIMI Technology, Hongqi Chain, and Tianli International Holdings [1] - The listed unicorns are distributed across 126 cities in China, with a total value of 24 trillion yuan, and an average age of 19 years, which is 9 years older than those on the 2025 Hurun Global Unicorn List [1] Group 3 - The top five industries with the most companies on the list are semiconductors, industrial equipment, biotechnology, new energy, and software services, accounting for 46% of the total [1] - The highest valued industries among the listed companies are semiconductors, new energy, industrial equipment, consumer electronics, and biotechnology [1]